Oruka Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-41.21Mn |
Net Profit Margins | -Inf% |
Oruka Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Oruka Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Oruka Therapeutics, Inc. Common Stock’s net profit fell -67.68% since last year same period to $-41.21Mn in the Q2 2026. On a quarterly growth basis, Oruka Therapeutics, Inc. Common Stock has generated -29.5% fall in its net profits since last 3-months.
Oruka Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Oruka Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Current Year | -0.49 |
Oruka Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.49 - a 9.26% jump from last quarter’s estimates.
Oruka Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.49.
Key Ratios
Earning Per Share (EPS) | -0.55 |
Oruka Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -19.57% since last year same period to -0.55 in the Q2 2026. This indicates that the Oruka Therapeutics, Inc. Common Stock has generated -19.57% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-03-31 | -0.54 | -0.48 | 11.11% |
2026-06-30 | -0.49 | -0.55 | -12.24% |
